Free Trial

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte logo
$33.74
-1.26 (-3.60%)
(As of 05:17 PM ET)

Veracyte - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
0
Buy
6

Based on 7 Wall Street analysts who have issued ratings for Veracyte in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a buy rating for VCYT.

Consensus Price Target

$35.67
5.71% Upside
According to the 7 analysts' twelve-month price targets for Veracyte, the average price target is $35.67. The highest price target for VCYT is $43.00, while the lowest price target for VCYT is $26.00. The average price target represents a forecasted upside of 5.71% from the current price of $33.74.
Get the Latest News and Ratings for VCYT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Veracyte and its competitors.

Sign Up

VCYT Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$35.67$31.25$27.50$31.29
Forecasted Upside5.71% Upside-5.67% Downside27.31% Upside48.56% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

VCYT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VCYT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Veracyte Stock vs. The Competition

TypeVeracyteMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside5.09% Upside15,773.04% Upside10.09% Upside
News Sentiment Rating
Positive News

See Recent VCYT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/17/2024Leerink Partners
1 of 5 stars
 Boost TargetOutperform ➝ Outperform$35.00 ➝ $40.00+16.41%
10/16/2024UBS Group
4 of 5 stars
L. Li
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$43.00+26.21%
10/10/2024Guggenheim
3 of 5 stars
S. Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00+25.31%
8/28/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$31.00 ➝ $37.00+15.62%
8/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$21.00 ➝ $26.00-11.74%
4/15/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$32.00 ➝ $28.00+41.34%
2/23/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/10/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$34.00+51.52%
1/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$33.00+38.83%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:38 PM ET.


VCYT Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Veracyte is $35.67, with a high forecast of $43.00 and a low forecast of $26.00.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There is currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares.

According to analysts, Veracyte's stock has a predicted upside of 5.71% based on their 12-month stock forecasts.

Veracyte has been rated by research analysts at Guggenheim, Leerink Partners, Morgan Stanley, Needham & Company LLC, and UBS Group in the past 90 days.

Analysts like Veracyte less than other "medical" companies. The consensus rating score for Veracyte is 2.71 while the average consensus rating score for "medical" companies is 2.79. Learn more on how VCYT compares to other companies.


This page (NASDAQ:VCYT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners